Company news

Tempus AI, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

New Study Shows Impact of Ambry Genetics’ Patient for Life™ Program on Rare Disease Diagnosis

May 27, 2025

Tempus to Present at the William Blair 45th Annual Growth Stock Conference

May 20, 2025

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

May 19, 2025

Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline

May 13, 2025

Tempus Announces Six Posters Accepted for Presentation at ISPOR 2025

May 12, 2025

Tempus Reports First Quarter 2025 Results

May 5, 2025

Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry

May 4, 2025

Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment

April 30, 2025

Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection

April 28, 2025

Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform

April 27, 2025

Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

April 24, 2025

Tempus to Report First Quarter 2025 Financial Results on May 6

April 23, 2025

Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology

April 22, 2025

Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.

April 17, 2025

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation

April 14, 2025

Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting

March 28, 2025

Tempus to Present at the 24th Annual Needham Virtual Healthcare Conference

March 25, 2025

Tempus Announces Acquisition of Deep 6 AI

March 10, 2025

Tempus Reports Fourth Quarter and Full Year 2024 Results

February 23, 2025

Tempus to Present at TD Cowen's 45th Annual Health Care Conference

February 18, 2025

Tempus to Participate in the Morgan Stanley Technology, Media and Telecom Conference

February 17, 2025

Tempus Announces Collaboration with IFLI Aimed at Supporting Development of Targeted Therapies for Follicular Lymphoma

February 12, 2025

Tempus to Report Fourth Quarter and Full Year 2024 Financial Results on February 24

February 10, 2025

Tempus Completes Acquisition of Ambry Genetics

February 2, 2025

Tempus Announces National Launch of olivia, its AI-enabled Personal Health Concierge App for Patients

January 20, 2025

Tempus Announces the National Launch of FDA-Approved xT CDx Test

January 14, 2025

Tempus One Introduces New GenAI Capabilities to Query Millions of Unstructured Documents for Research and Clinical Care

January 13, 2025

Tempus Announces Preliminary Fourth Quarter and Full Year 2024 Results

January 12, 2025

Tempus Announces Its First-Ever, Whole-Genome Sequencing Assay, xH

January 12, 2025

Tempus Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms

January 7, 2025

Tempus to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025

Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions

December 17, 2024

New CMS Decision Provides Medicare Coverage for the Clinical Use of the Tempus ECG-AF Device

December 16, 2024

Personalis and Tempus Expand Collaboration to Biopharma

December 15, 2024

Tempus to Participate in the Piper Sandler 36th Annual Healthcare Conference

November 24, 2024

Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR®

November 11, 2024

Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care

November 10, 2024

Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting

November 7, 2024

Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test

November 6, 2024

Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics

November 3, 2024

Tempus to Report Third Quarter 2024 Financial Results on November 4

November 2, 2024

Tempus to Report Third Quarter 2024 Financial Results on November 7

October 23, 2024

Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development

September 25, 2024

Tempus Announces Four Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2024

September 12, 2024

Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients

September 11, 2024

Tempus Announces Real World Data Collaboration with BioNTech

September 3, 2024

Tempus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

August 27, 2024

Personalis and Tempus Announce Expanded Collaboration

August 15, 2024

NPJ Precision Oncology Publishes Tempus Study on Validation of its HLA-LOH Investigational Assay

August 7, 2024

Tempus Reports Second Quarter 2024 Results

August 5, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 10 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.